OncoMed Pharmaceuticals Inc. (OMED)
Symbol Info
Listed Symbol OMED
Name OncoMed Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $44,421,000
Latest Fiscal EPS $-0.21
Price Info
21 Day Moving Average $0.9860
21 Day EMA $0.940510
50 Day Moving Average $0.9222
50 Day EMA $0.937490
200 Day EMA $1.462670
200 Day Moving Average 1.496280
52 Week High $3.35
52 Week Low $0.55
52 Week Change $-70.033700
Alpha -0.046693
Beta 1.7503
Standard Deviation 0.196358
R2 0.083696
Periods 60
Share Information
10 Day Average Volume 943,996
20 Day Average Volume 656,682
30 Day Average Volume 574,423
50 Day Average Volume 583,385
Outstanding Shares 38,690,089
Float Shares 37,755,798
Percent Float 97.59%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 102
Institute Holdings Date 2019-03-31
Institute Bought Previous 3 Months 780,041
Institute Holdings Percent 46.600000
Institute Sold Previous 3 Months 2,049,170
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 934,291
Price Change
7 Day Price Change $-
7 Day Percent Change -
21 Day Price Change $-0.12
21 Day Percent Change -11.88%
30 Day Price Change $-0.15
30 Day Percent Change -14.42%
Month To Date Price Change $-0.15
Month To Date Percent -14.42%
90 Day Price Change $0.128200
90 Day Percent Change 16.83%
Quarter To Date $-0.15
Quarter To Date Percent -14.42%
180 Day Price Change $-0.75
180 Day Percent Change -45.73%
200 Day Price Change $-1.1
200 Day Percent Change -55.28%
Year To Date $0.142700
Year To Date Percent 19.10%
Profile
Description OncoMed Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. The company's therapeutic candidates and preclinical programs include Navicixizumab, Anti-TIGIT, GITRL-Fc, and Rosmantuzumab.
Details
Issue Type CS
Market Cap $34,434,179
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 38,690,089
CEO
Employees 22
Last Audit UE
Classification
CIK 0001302573
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 800 Chesapeake Drive
Redwood City, CA 94063
Website http://www.oncomed.com
Facisimile +1 650 298-8600
Telephone +1 650 995-8200
Email ir@oncomed.com
Key Ratios
Profitability
EBIT Margin -18.4
EBITDA Margin -14.6
Pre-Tax Profit Margin -203.7
Profit Margin Cont -7.83
Gross Margin -
Profit Margin TOT -7.83
Income Statements
Revenue $36,572,000
Revenue Per Share $0.9453
Revenue 3 Years $27.69
Revenue 5 Years $0.76
Valuation Measures
PE Ratio -
Enterprise Value $-22,910,821
Price To Sales 0.941545
Price To Free Cash -1.1
PE High Last 5 Years -
Price To Book 0.7
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 0.7
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 5.0
Leverage Ratio 1.6
Quick Ratio 4.8
Long Term Debt To Capital -
Assets
Receivables Turnover 21.7
Invoice Turnover -
Assets Turnover 0.40
Management Effectiveness
Return Assets -9.49
Return On Equity -950.03
Return On Capital -5.36
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type
Your Recent History
NASDAQ
OMED
ONCOMED PH..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

Finance Manila is owned and operated by ADVFN PLC.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:fm D:20191016 01:07:30